UCLA SPORE in Prostate Cancer

UCLA SPORE 在前列腺癌中的应用

• 批准号: 9792320
• 负责人: ROBERT E REITER
• 金额: $ 170.87万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9792320
• 关键词: Androgen Receptor; Antibodies; Area; Bioinformatics; Biometry; CAR T cell therapy; California; Cancer Patient; Castration; Cell Nucleus; Chemistry; Cities; Clinic; Clinical; Development; Diagnosis; Discipline; Disease; Drug Targeting; Environment; FDA approved; FOLH1 gene; Fat-Restricted Diet; Fostering; Funding; Goals; Human; Image; Immunotherapy; Infrastructure; Institution; Interdisciplinary Study; Laboratory Research; Lymphoma; MAP Kinase Gene; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Measurable; Morbidity - disease rate; Nanotechnology; Neoplasm Metastasis; Neurosecretory Systems; Omega-3 Fatty Acids; Outcome; PTEN gene; Pathology; Pathway interactions; Play; Prostate; Prostate Cancer therapy; Radiology Specialty; Reproduction spores; Research; Research Personnel; Research Support; Resistance; Scientist; Signal Transduction; Sister; Specimen; Talents; Technology; Translational Research; Translations; Work; antibody engineering; anticancer research; biomarker-driven; cancer stem cell; career development; combat; data management; design; drug development; human capital; improved; innovation; men; mortality; neuroendocrine phenotype; new technology; novel; novel strategies; outcome forecast; pre-clinical; prevent; programs; prostate cancer metastasis; prostate stem cell antigen; radioligand; research and development; stem cell biology; targeted treatment; therapy resistant; translational impact; translational research program

OVERALL SUMMARY/ABSTRACT The UCLA Prostate Cancer SPORE is a multidisciplinary and translational research program focused on the development of new and innovative approaches for improving the diagnosis, prognosis, and treatment of prostate cancer patients. The program’s reach includes collaborating investigators at local institutions such as Cedars Sinai and City of Hope in order to accelerate the goal of combating prostate cancer. A particular strength of the UCLA Prostate Cancer SPORE has been its ability to leverage institutional and NCI support to attract new human capital, technology, and ideas to the field of prostate cancer. Examples of these discoveries include: (1) the development of both the androgen receptor (AR) super-antagonists enzalutamide and apalutamide, (2) the discovery of the putative human prostate cancer stem cell of origin and its association with emergence of the lethal neuroendocrine phenotype, (3) the translation of novel engineered antibodies targeting Prostate Stem Cell Antigen (PSCA) to the clinic to target, treat and image prostate (and pancreatic) cancer, (4) the elucidation of signaling cross-talk between the PTEN/PI3K, AR, and ras/MAPK pathways in castrate resistant and treatment resistant prostate cancer (CRPC), and (5) the demonstration that a low fat diet supplemented with omega-3 fatty acids has measurable effects on prostate cancer and its mechanism of action. The overall goal of this competitive renewal application is to continue to apply the diversity of talent on the UCLA campus, its sister institutions and other institutions in Southern California to the critical and evolving translational challenges in the field of prostate cancer. To achieve the long-term objectives and goals of our program, the Specific Aims of the UCLA SPORE in Prostate Cancer are: (1) to perform high-impact translational research focused on some of the major challenges in the field of prostate cancer such as cancer metastasis, castration resistance, and treatment resistance, (2) to provide organizational infrastructure and novel technologies designed specifically to support the translational research objectives of the SPORE such as administrative, fiscal, and statistical support, and (3) to develop new prostate cancer researchers and research areas to advance translational research in prostate cancer through supporting innovative research in critical areas, pilot developmental research, and career development in prostate cancer research. Through these aims, UCLA Prostate Cancer SPORE can continue to promote significant and novel discoveries with potential major impact on men with prostate cancer.

总体摘要/摘要 加州大学洛杉矶分校前列腺癌孢子是一个多学科和转化性的研究项目，专注于 开发新的和创新的方法来改善前列腺癌的诊断、预后和治疗 癌症患者。该项目的覆盖范围包括与雪松等当地机构的合作调查人员 西奈半岛和希望之城，以加快实现抗击前列腺癌的目标。它的一个特殊优势是 加州大学洛杉矶分校前列腺癌孢子一直有能力利用机构和NCI的支持来吸引新的人类 资金、技术和理念投向前列腺癌领域。这些发现的例子包括：(1) 雄激素受体(AR)超拮抗剂苯扎鲁胺和阿帕鲁胺的开发，(2) 人类前列腺癌干细胞来源的发现及其与前列腺癌发生的关系 致死性神经内分泌表型，(3)针对前列腺干细胞的新型工程抗体的翻译 抗原(PSCA)用于临床靶向、治疗和成像前列腺癌(和胰腺癌)，(4)阐明 PTEN/PI3K、AR和ras/MAPK信号通路在去势抵抗和治疗中的信号串扰 耐药前列腺癌(CRPC)，以及(5)证明低脂肪饮食中添加omega-3脂肪 酸对前列腺癌及其作用机制有可测量的影响。 此次竞争性续签申请的总体目标是继续将多样化的人才应用于加州大学洛杉矶分校 校园、其姊妹机构和南加州的其他机构对关键和不断发展的翻译 前列腺癌领域的挑战。为了实现我们计划的长期目标和目标， 加州大学洛杉矶分校的孢子在前列腺癌中的具体目的是：(1)进行高影响力的翻译研究 重点关注前列腺癌领域的一些主要挑战，如癌症转移、去势 抗药性和治疗抗性，(2)提供组织基础设施和新技术 专为支持孢子的翻译研究目标而设计，如行政、财政、 和统计支持，以及(3)开发新的前列腺癌研究人员和研究领域以推进 通过支持关键领域的创新研究进行前列腺癌的转化性研究，试点 前列腺癌研究中的发展研究和职业发展。通过这些目标，加州大学洛杉矶分校 前列腺癌孢子可以继续促进具有潜在重大影响的重大和新发现 患有前列腺癌的男性。